Chemical Compound Review:
Rapaflo 1-(3-hydroxypropyl)-5-[(2R)- 2-[2-[2-(2,2,2...
Synonyms:
Silodosin, Silodyx, Rapflo, Urorec, Urief, ...
- A selective alpha1A-adrenoceptor antagonist inhibits detrusor overactivity in a rat model of benign prostatic hyperplasia. Tatemichi, S., Akiyama, K., Kobayashi, M., Yamazaki, Y., Yokoyama, O., Uruno, T. J. Urol. (2006)
- Effects of KMD-3213, a uroselective alpha 1A-adrenoceptor antagonist, on the tilt-induced blood pressure response in normotensive rats. Akiyama, K., Hora, M., Yamagishi, R., Kitazawa, M. Jpn. J. Pharmacol. (2002)
- KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues. Shibata, K., Foglar, R., Horie, K., Obika, K., Sakamoto, A., Ogawa, S., Tsujimoto, G. Mol. Pharmacol. (1995)
- Identification of alpha-1L and alpha-1A adrenoceptors in human prostate by tissue segment binding. Morishima, S., Tanaka, T., Yamamoto, H., Suzuki, F., Akino, H., Yokoyama, O., Muramatsu, I. J. Urol. (2007)
- Alpha-1 adrenoceptor up-regulation induced by prazosin but not KMD-3213 or reserpine in rats. Zhang, L., Taniguchi, T., Tanaka, T., Shinozuka, K., Kunitomo, M., Nishiyama, M., Kamata, K., Muramatsu, I. Br. J. Pharmacol. (2002)
- Silodosin, a new alpha-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. Kawabe, K., Yoshida, M., Homma, Y. BJU Int. (2006)
- Tissue selectivity of KMD-3213, an alpha(1)-adrenoreceptor antagonist, in human prostate and vasculature. Murata, S., Taniguchi, T., Takahashi, M., Okada, K., Akiyama, K., Muramatsu, I. J. Urol. (2000)
- Uroselectivity in male dogs of silodosin (KMD-3213), a novel drug for the obstructive component of benign prostatic hyperplasia. Tatemichi, S., Tomiyama, Y., Maruyama, I., Kobayashi, S., Kobayashi, K., Maezawa, A., Kobayashi, M., Yamazaki, Y., Shibata, N. Neurourol. Urodyn. (2006)
- Effect of KMD-3213, an alpha 1a-adrenoceptor-selective antagonist, on the contractions of rabbit prostate and rabbit and rat aorta. Yamagishi, R., Akiyama, K., Nakamura, S., Hora, M., Masuda, N., Matsuzawa, A., Murata, S., Ujiie, A., Kurashina, Y., Iizuka, K., Kitazawa, M. Eur. J. Pharmacol. (1996)
- In vivo receptor binding of novel alpha1-adrenoceptor antagonists for treatment of benign prostatic hyperplasia. Yamada, S., Ohkura, T., Kimura, R., Kawabe, K. Life Sci. (1998)
- Selective and sustained occupancy of prostatic alpha1-adrenoceptors by oral administration of KMD-3213 and its plasma concentration in rats. Okura, T., Yamada, S., Abe, Y., Kimura, R. J. Pharm. Pharmacol. (2002)
- Pharmacological analysis of the novel, selective alpha1-adrenoceptor antagonist, KMD-3213, and its suitability as a tritiated radioligand. Murata, S., Taniguchi, T., Muramatsu, I. Br. J. Pharmacol. (1999)
- Differences in the subcellular localization of alpha1-adrenoceptor subtypes can affect the subtype selectivity of drugs in a study with the fluorescent ligand BODIPY FL-prazosin. Sugawara, T., Hirasawa, A., Hashimoto, K., Tsujimoto, G. Life Sci. (2002)